Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== New Zealand === The opposition Green Party of Aotearoa New Zealand's co-leader, Marama Davidson, stated "this is a unilateral attack that goes against any enduring pathway to international peace through justice." She called upon Prime Minister Christopher Luxon to condemn the United States for attacking Venezuela.
Herbal medicine (also called herbalism, phytomedicine or phytotherapy) is the study of pharmacognosy and the use of medicinal plants, which are a basis of traditional medicine. Scientific evidence for the effectiveness of many herbal treatments remains limited, prompting ongoing regulatory evaluation and research into their safety and efficacy. Standards for purity or dosage are generally not provided. The scope of herbal medicine sometimes includes fungal and bee products, as well as minerals, shells and certain animal parts. Paraherbalism is the pseudoscientific use of plant or animal extracts as medicine, relying on unproven beliefs about the safety and effectiveness of minimally processed natural substances. Herbal medicine has been used since at least the Paleolithic era, with written records from ancient Sumer, Egypt, Greece, China, and India documenting its development and application over millennia. Modern herbal medicine is widely used globally, especially in Asia and Africa. Traditional medicine systems involve long-standing, culturally-embedded practices using local herbs, animal products, and spiritual elements. These systems have influenced and contributed to modern pharmacology. Herbalists believe that plants, having evolved defenses against environmental stressors, produce beneficial phytochemicals, often extracted from roots or leaves, that can be used in medicine.
The company began as a collaboration between a group of entrepreneurs, the professional artist Joseph Lyons and his brothers in law, Isidore and Montague Gluckstein, as a spin off from the Salmon & Gluckstein tobacco company. In 1894 the company started a teashop in Piccadilly, London, and from 1909 developed this into a chain of teashops which would ultimately number around 200 locations. The company also ran high class restaurants, founding the Trocadero in 1895, and hotels including the Strand Palace, opened in 1909, the Regent Palace, opened in 1915, and the Cumberland Hotel, opened in 1933, all in London. In 1918, to increase sales in northern England, Lyons bought the old established tea company Horniman & Sons. From the 1930s Lyons began to develop a pioneering range of teas, biscuits and cakes that were sold in grocery stores across the world. Lyons was appointed to run the company, and it was named after him. J. Lyons & Co. was a pioneer in introducing computers to business. Between 1951 and 1963, the company manufactured and sold a range of LEO (Lyons Electronic Office) computers.
Fishbone is the recording debut of alternative group Fishbone. This six-song EP was released in 1985 and captures the band at the height of their early funk/ska era. The track "Party at Ground Zero" remains one of the band's most popular tracks. The track "V.T.T.L.O.T.F.D.G.F." stands for "Voyage to the Land of the Freeze-Dried Godzilla Farts", as confirmed on the band's website, and imagines a government attempt to convince the public that Hiroshima was actually caused by Godzilla farting.
=== Image production === Images are constructed by plotting ion intensity versus relative position of the data from the sample. Spatial resolution highly impacts the molecular information gained from analysis.
Sources: en.wikipedia.org
He also learns that Wellington Wells is slowly falling apart; the city's infrastructure is failing, an unspecified disease outbreak has occurred, and Joy is becoming less effective, with scientist Anton Verloc (Michael Shaeffer) researching a new version of Joy to permanently lobotomize the populace and keep them in a never-ending state of euphoria. Eventually, Arthur reaches a railway bridge leading out of Wellington Wells, and recalls that he swapped his identity card (which stated his age as 12) with Percy's (who had just turned 13) before the children of Wellington Wells boarded the fateful train to Germany, effectively sacrificing his brother to save himself. Sally's Story: The creator of a new brand of Joy, Sally Boyle (Charlotte Hope), works as an experimental chemist in her laboratory after being kicked out of Haworth Labs by its director, Anton Verloc. The local police constabulary threaten Sally into supplying them with her Joy, which forces her to scrounge the city for new ingredients to create a fresh batch. Sally is secretly a mother to the first baby born in Wellington Wells in a long time: Gwen, who Verloc fathered. When Gwen becomes sick with measles, Sally asks Arthur, her childhood friend, to find a bottle of cod liver oil. Arthur, not knowing it is for Gwen, agrees in return for a Letter of Transit from General Robert Byng (Stephen Boxer), Sally's most prominent patron and on-and-off lover. Sally eventually remembers how her mother poisoned her family when she and her siblings were to be taken to Germany, leaving Sally as the sole survivor.
=== Railway === Wilmslow railway station lies on the Crewe to Manchester spur of the West Coast Main Line, via Stockport. The station is also a junction for the Styal Line, which takes a different route to Manchester Piccadilly, via Styal, Manchester Airport and Heald Green, but avoiding Stockport. The station is served by three train operating companies:
=== In organic synthesis === Chloral hydrate is a starting point for the synthesis of other organic compounds. It is the starting material for the production of chloral, which is produced by the distillation of a mixture of chloral hydrate and sulfuric acid, which serves as the desiccant. Notably, it is used to synthesize isatin. In this synthesis, chloral hydrate reacts with aniline and hydroxylamine to give a condensation product which cyclicizes in sulfuric acid to give the target compound:
The characterization of the caspases allowed the development of caspase inhibitors, which can be used to determine whether a cellular process involves active caspases. Using these inhibitors, it was discovered that cells can die while displaying a morphology similar to apoptosis without caspase activation. Later studies linked this phenomenon to the release of AIF (apoptosis-inducing factor) from the mitochondria and its translocation into the nucleus mediated by its nuclear localization signal (NLS). Inside the mitochondria, AIF is anchored to the inner membrane. In order to be released, the protein is cleaved by a calcium-dependent calpain protease. Anoikis Apaf-1 Apo2.7 Apoptotic DNA fragmentation Atromentin induces apoptosis in human leukemia U937 cells. Autolysis Autophagy Cisplatin Cytotoxicity Entosis Ferroptosis Homeostasis Immunology Necrobiosis Necrosis Necrotaxis Nemosis Mitotic catastrophe p53 Paraptosis Pseudoapoptosis PI3K/AKT/mTOR pathway Ruptosis
Introduced in 2007, ChIP sequencing (ChIP-seq) is a technology that uses chromatin immunoprecipitation to crosslink the proteins of interest to the DNA but then instead of using a micro-array, it uses the more accurate, higher throughput method of sequencing to localize interaction points. DamID is an alternative method that does not require antibodies. ChIP-exo uses exonuclease treatment to achieve up to single base pair resolution. CUT&RUN sequencing uses antibody recognition with targeted enzymatic cleavage to address some technical limitations of ChIP.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.